Shattuck (STTK) Climbs 59% After Positive Data from Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with AZA in HR-MDS and TP53m AML
Tweet Send to a Friend
Shattuck (NASDAQ: STTK) Climbs 59% After Positive Data from Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with AZA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
